v3.21.1
Stock-Based Compensation
3 Months Ended
May 01, 2021
Equity [Abstract]  
Stock-Based Compensation

NOTE 4. Stock-Based Compensation

The Company’s 2015 Equity Incentive Plan (the “Plan”) was approved by stockholders in June 2015. The Plan is an omnibus plan that allows for grants of stock options, stock appreciation rights, stock awards, restricted stock, stock units and performance units.  As of May 1, 2021, options to purchase 855,000 shares and 3,000 unvested restricted shares were outstanding under the 2015 Plan and 1,081,000 shares were available for future grant.

 

During the 13-week period ended May 2, 2020, the Company made grants of unregistered shares to advisors associated with the March 2020 debt restructuring in the aggregate amount of 300,000 shares, and a corresponding reduction of warrants on 300,000 shares previously issued to the advisors.  On a combined basis, the shares issued were valued at $216,000, and the warrant reductions were valued at $89,000, resulting in a net compensation expense of $127,000.  Additional expense for restricted shares vesting during the period amounted to $24,000, bringing total stock-based compensation to $151,000.

No grants of options or shares were made during the 13-week period ended May 1, 2021.  Stock-based compensation expense for the period for vesting of stock options and restricted stock amounted to $37,000.

A summary of option activity under the 2015 Plan as of May 1, 2021 and changes during the 13 weeks then ended are presented in the table below (shares in thousands):

 

 

Shares

 

 

Wtd. Avg. Exercise Price

 

 

Wtd. Avg. Remaining Contractual Life in Years

 

 

Aggregate Intrinsic Value (a)

 

Outstanding at January 30, 2021

 

 

855

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expired/Forfeited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at May 1, 2021

 

 

855

 

 

$

1.676

 

 

 

4.49

 

 

$

2,089

 

Vested and expected to vest

 

 

855

 

 

$

1.676

 

 

 

4.49

 

 

$

2,089

 

Exercisable at May 1, 2021

 

 

707

 

 

$

1.690

 

 

 

4.51

 

 

$

1,720

 

Non-vested at May 1, 2021 (b)

 

 

148

 

 

$

1.611

 

 

 

4.44

 

 

$

369

 

 

 

(a)

The aggregate intrinsic value is based on our closing stock price of $4.103 as of May 1, 2021.

 

(b)

Weighted average grant-date fair value is $0.81 per share.